Health Canada — Medical Devices · Canada · 2016-11-03 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Archived by the issuing authority — kept for reference
Reported risk: The manufacturer reports that lot 4515.61.1 containing cells with a CCD.ee phenotype could react much more weakly during antibody screening with anti-E (anti-RH3). It is suspected that the donor's red blood cells present a Big E variant (weak ew score). Weaker reactions or even false negatives could be observed during testing, which would complicate pretransfusion analyses.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.